Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

18.71USD
22 Mar 2017
Change (% chg)

$-0.44 (-2.30%)
Prev Close
$19.15
Open
$18.98
Day's High
$19.14
Day's Low
$18.30
Volume
115,498
Avg. Vol
99,717
52-wk High
$23.75
52-wk Low
$6.02

Latest Key Developments (Source: Significant Developments)

Zynerba enters into an open market sale agreement with Jefferies
Friday, 2 Sep 2016 

Zynerba Pharmaceuticals Inc : Entered into an open market sale agreement with Jefferies Llc, or Jefferies, as placement agent - SEC filing .Pursuant to agreement co may issue, sell shares of common stock in an aggregate offering price of up to $30.0 million.  Full Article

Zynerba Pharmaceuticals files for mixed shelf of up to $150 mln
Friday, 2 Sep 2016 

Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals Inc files for mixed shelf of up to $150 million -SEC filing.  Full Article

Zynerba Pharmaceuticals reported Q2 EPS ($0.70)
Thursday, 11 Aug 2016 

Zynerba Pharmaceuticals Inc : Q2 loss per share $0.70 . Zynerba Pharmaceuticals reports second quarter 2016 financial results and organizational changes . Q2 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S . Expects its existing cash and cash equivalents will fund its research and development programs and operations through 2017 .Jim Fickenscher will replace Richard Baron as Chief Financial Officer.  Full Article

Zynerba Pharma Q1 loss per share $0.49
Thursday, 12 May 2016 

Zynerba Pharmaceuticals Inc : Expects that existing cash and cash equivalents will fund its research and development programs and operations through 2017 . Zynerba pharmaceuticals reports first quarter 2016 financial results and operational highlights . Q1 loss per share $0.49 .Q1 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S.  Full Article

Zynerba Pharmaceuticals Inc announces positive initial results from ZYN002 CBD Gel Phase 1 Single Rising Dose Trial
Thursday, 7 Jan 2016 

Zynerba Pharmaceuticals Inc:Announced positive initial safety results from its Phase 1 single rising dose clinical trial of its ZYN002 cannabidiol (CBD) gel in development for the treatment of epilepsy, osteoarthritis and Fragile X Syndrome.Final results, including results from patients with epilepsy, are expected in the first half of 2016.  Full Article

Zynerba Pharmaceuticals initiates Phase 1 clinical trial for ZYN002 CBD Gel
Tuesday, 20 Oct 2015 

Zynerba Pharmaceuticals:Initiates Phase 1 clinical trial for ZYN002 CBD Gel.Results are expected in the first half of 2016.  Full Article

Zynerba Pharmaceuticals announces pricing of its initial public offering
Wednesday, 5 Aug 2015 

Zynerba Pharmaceuticals Inc:Announces pricing of its initial public offering.Says initial public offering of 3 million common shares priced at $14.00 per share.  Full Article

More From Around the Web

BRIEF-Zynerba Pharmaceuticals completes enrollment for ZYN002 in two phase 2 clinical trials for epilepsy and osteoarthritis

* Zynerba Pharmaceuticals announces completion of enrollment for ZYN002 in two Phase 2 clinical trials for epilepsy and osteoarthritis Source text for Eikon: Further company coverage: